HealthCare Global Enterprises (HCG) has updated its investor presentation related to the unaudited financial results for Q3 and nine months ended December 31, 2025. The updated presentation incorporates clarifications and corrections, superseding the earlier version. Key highlights of the company’s performance and strategic outlook are included in the presentation.
Financial Performance
HCG reported revenue of INR 6,331 million for Q3 FY26, reflecting a growth of approximately 13% year-over-year. Excluding Milann, the YoY revenue growth was also around 13%, driven by an 8% increase in volumes and a 5% increase in ARPP.
Adjusted EBITDA for Q3 FY26 was INR 1,108 million, up from INR 923 million in Q3 FY25, showcasing a growth of about 20% YoY.
Cluster Performance
The West cluster showed revenue growth of approximately 17% YoY and remained the largest, while the South cluster (constituting 39% of revenue) grew by around 9%.
The East cluster (11% of revenue) experienced a 12% YoY revenue increase, and the International business grew by approximately 42% YoY.
Key Financial Metrics (9MFY26)
ARPP: INR 83,684 (+3% YoY)
Volume: 221k (+13% YoY)
Revenue: INR 18,931 Mn (+16% YoY)
Adj. EBITDA: INR 3,458 Mn (+20% YoY)
ROCE (Pre-Tax): 13.3%
Strategic Updates
HCG has strengthened its leadership team with key additions in marketing, sales, and international business, along with roles in finance, technology, and clinical strategy.
The North Bangalore Greenfield Hospital is on track and will offer MR-LINAC technology. Operations are expected to begin by the end of Q4FY26. Source: BSE
